08:02 AM EDT, 10/03/2025 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Friday it has been granted fast-track designation for ALTO-101 for the treatment of cognitive impairment associated with schizophrenia by the US Food and Drug Administration.

Phase 1 data for the treatment showed significant and clinically relevant effects on both electroencephalogram measures and cognitive performance in healthy subjects and provides "strong validation" for its mechanism, according to Alto Neuroscience ( ANRO ) CEO Amit Etkin.

The company said enrollment is ongoing for the phase 2 proof-of-concept study for the treatment of patients with cognitive impairment associated with schizophrenia.

The company's shares were up more than 7% in recent premarket activity on Friday.